AcquisitionThe company confirms the acquisition deal with NVS is on track to close.
RegulatoryThe NDA filing for pelabresib is expected.
ValuationAnalysts reiterate a €68 price target based on the NVS acquisition.
Bears Say
Clinical CautionClinicians would likely remain cautious about adding pelabrasib to Jakafi until the true long-term safety of the regimen has been established.
Regulatory ConcernsA warning letter was issued by the FDA to physicians involved in the MANIFEST-2 trial.
Safety IssuesPhysicians involved in the trial disclosed multiple cases of AML transformation in the Phase 3 MANIFEST-2.
What was Morphosys AG’s price range in the past 12 months?
Morphosys AG lowest share price was €14.55 and its highest was €69.65 in the past 12 months.
What is Morphosys AG’s market cap?
Currently, no data Available
When is Morphosys AG’s upcoming earnings report date?
Morphosys AG’s upcoming earnings report date is Aug 29, 2024 which is in 37 days.
How were Morphosys AG’s earnings last quarter?
Morphosys AG released its earnings results on Apr 29, 2024. The company reported -€8.27 earnings per share for the quarter, missing the consensus estimate of -€1.129 by -€7.141.
How many shares outstanding does Morphosys AG have?
Morphosys AG has 37,716,423 shares outstanding.
What happened to Morphosys AG’s price movement after its last earnings report?
Morphosys AG reported an EPS of -€8.27 in its last earnings report, missing expectations of -€1.129. Following the earnings report the stock price went up 1.223%.
Which hedge fund is a major shareholder of Morphosys AG?
Currently, no hedge funds are holding shares in GB:0NDV
MorphoSys AG is a biotechnology company that develops therapeutic antibodies. The company reports two business segments: partnered discovery and proprietary development. Its partnered discovery segment applies the research, development, and optimization of antibody-drug candidates in partnerships with pharmaceutical and biotechnology companies. MorphoSys' profits in this segment stem from successful programs via milestone payments and potential royalties on product sales. In its proprietary development segment, the company develops antibodies that concentrate on inflammatory and autoimmune diseases, as well as cancer and infectious diseases.
Copying James Gordon's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +13.92% per trade.